These findings provide evidence for a functional crosstalk between the PD-1 and CTLA-4 inhibitory receptors that depend on the abundance of PD-L1 and B7–1 expression on cancer cells or APC, and support the rationale for combining blockade of PD-L1 and CTLA-4 to improve clinical outcomes of tumor immunotherapy. The gene discussed is CD274; the disease is cancer.